Companies ›Healthcare ›CGEN.NR

CGEN.NR — — Biotechnology & Life-Science Tools

Car & General (Kenya) PLC

$79,25

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

4,26 %

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

483

Day range

$2,65–$2,73

Prev close

$2,65

Open

$2,72

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Car & General (Kenya) PLC operates in the auto, truck, and motorcycle parts industry, providing automotive components and related services to customers in Kenya and potentially across East Africa.

Business. Car & General (Kenya) PLC (CGEN.NR) operates in the Health Care sector, specifically within the Biotechnology & Life-Science Tools industry. The company generates revenue through a product-sale model. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data. Consequently, the business is described at the industry level without further geographic or structural breakdown.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

Northern Trust Investments, Inc.

largest disclosed fund holder

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CGEN.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CGEN.NR. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Car & General (Kenya) PLC (CGEN.NR) operates in the Health Care sector, specifically within the Biotechnology & Life-Science Tools industry. The company generates revenue through a product-sale model. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data. Consequently, the business is described at the industry level without further geographic or structural breakdown.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

AI synthesis

GENERATED

Car & General (Kenya) PLC has a fully diluted share count of 80,206,616, with no additional shares outstanding in the diluted structure, indicating no immediate dilution pressure from stock options or convertible instruments. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents, which limits the ability to evaluate the company's short-term financial flexibility.

Profitability and return metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. This lack of data prevents a direct comparison of the company's performance against industry medians or benchmarks.

The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk associated with over-reliance on specific markets or customer segments.

Growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or directional guidance. Without historical revenue data or forward-looking statements, it is challenging to determine the company's growth potential or trajectory.

The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unassessed. No dilution sources are identified in the available documents, and no adjustments are applied in the custom valuations, suggesting that the company has not issued new shares recently or disclosed plans for future equity raises.

Recent events, including filings or transcripts, are not available in the provided data, which limits the ability to assess the company's strategic direction or operational developments in the near term.

Key takeaways

The company's liquidity risk remains unassessed due to missing balance-sheet data and lack of going-concern language.
No profitability or return metrics are available for comparison against industry benchmarks.
Revenue concentration and geographic exposure are not disclosed, limiting visibility into market risk.
Growth trajectory is unclear due to the absence of numeric deltas or directional guidance in the outlook.
Dilution risk is low, with no identified sources or recent equity issuance activity.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$79,25

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs CGEN · multiples and returns

IQV—

Iqvia Holdings Inc

$181,94

30,9B USD

P/E

22,7x

— vs self

Div yield

—

— vs self

ROE

21,9 %

-12,5 vs self

CRL—

Charles River Laboratories

$230,87

11,4B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-4,6 %

-39,0 vs self

MEDP—

Medpace Holdings Inc

$576,00

16,7B USD

P/E

34,4x

— vs self

Div yield

—

— vs self

ROE

75,4 %

+41,0 vs self

ALKS—

Alkermes PLC

$49,53

8,2B USD

P/E

39,8x

— vs self

Div yield

—

— vs self

ROE

8,4 %

-26,0 vs self

PIII—

P3 Health Partners Inc

$10,20

73,8M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

95,3 %

+60,9 vs self

ORGO—

Organogenesis Holdings Inc

$2,38

306,2M USD

P/E

9,0x

— vs self

Div yield

—

— vs self

ROE

8,5 %

-25,9 vs self

NAGE—

Niagen Bioscience Inc

$3,53

281,1M USD

P/E

17,4x

— vs self

Div yield

—

— vs self

ROE

22,7 %

-11,7 vs self

SPRY—

Ars Pharmaceuticals Inc

$5,51

547,1M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-149,9 %

-184,3 vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 46 000 sh13 exercises2 insiders

Ophir EranDirector, President and CEO · Share Option (right to buy) → Ordinary SharesDisposed 5 000 @ $0,83exercise · 2026-04-24
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 000 @ $1,15exercise · 2026-04-24
Ophir EranDirector, President and CEO · Share Option (right to buy) → Ordinary SharesDisposed 5 000 @ $0,83exercise · 2026-04-14
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 000 @ $1,15exercise · 2026-04-14
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 1 125 @ $0,83exercise · 2026-04-10
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 000 @ $1,15exercise · 2026-04-10
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 1 000 @ $1,15exercise · 2026-04-08
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 4 375 @ $0,83exercise · 2026-04-08
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 500 @ $0,83exercise · 2026-04-07
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 500 @ $0,83exercise · 2026-04-01
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 1 000 @ $1,15exercise · 2026-04-01
Ophir EranDirector, President and CEO · Share Option (right to buy) → Ordinary SharesDisposed 5 625 @ $0,83exercise · 2026-04-01
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 11 875 @ $0,83exercise · 2026-03-26

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Car & General (Kenya) PLC Market data — financials · 2026-05-27

Ownership & reference

Top holders

Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$2M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Anat Cohen-DayagPresident, Chief Executive Officer, Director

Insider activity

Net selling0 buys · 10 sellsnet -$114K2 insiders · last 365d

Levine ZuritSVP, Business Development · Ordinary SharesOther 2 000 @ $1,15$2K · 2026-04-24
Levine ZuritSVP, Business Development · Ordinary SharesSold 2 000 @ $3,20$6K · 2026-04-24
Ophir EranDirector, President and CEO · Ordinary SharesOther 5 000 @ $0,83$4K · 2026-04-24
Ophir EranDirector, President and CEO · Ordinary SharesSold 5 000 @ $3,20$16K · 2026-04-24
Ophir EranDirector, President and CEO · Ordinary SharesOther 5 000 @ $0,83$4K · 2026-04-14
Ophir EranDirector, President and CEO · Ordinary SharesSold 5 000 @ $2,90$15K · 2026-04-14
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 000 @ $1,15$2K · 2026-04-14
Levine ZuritSVP, Business Development · Ordinary SharesSold 2 000 @ $2,80$6K · 2026-04-14
Levine ZuritSVP, Business Development · Ordinary SharesOther 1 125 @ $0,83$933 · 2026-04-10
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 000 @ $1,15$2K · 2026-04-10
Levine ZuritSVP, Business Development · Ordinary SharesSold 3 125 @ $2,56$8K · 2026-04-10
Levine ZuritSVP, Business Development · Ordinary SharesOther 4 375 @ $0,83$4K · 2026-04-08
Levine ZuritSVP, Business Development · Ordinary SharesOther 1 000 @ $1,15$1K · 2026-04-08
Levine ZuritSVP, Business Development · Ordinary SharesSold 5 375 @ $2,42$13K · 2026-04-08
Levine ZuritSVP, Business Development · Ordinary SharesSold 2 500 @ $2,30$6K · 2026-04-07
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 500 @ $0,83$2K · 2026-04-07
Levine ZuritSVP, Business Development · Ordinary SharesOther 1 000 @ $1,15$1K · 2026-04-01
Ophir EranDirector, President and CEO · Ordinary SharesOther 5 625 @ $0,83$5K · 2026-04-01
Ophir EranDirector, President and CEO · Ordinary SharesSold 5 625 @ $2,21$12K · 2026-04-01
Levine ZuritSVP, Business Development · Ordinary SharesSold 3 500 @ $2,20$8K · 2026-04-01
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 500 @ $0,83$2K · 2026-04-01
Levine ZuritSVP, Business Development · Ordinary SharesOther 11 875 @ $0,83$10K · 2026-03-26
Levine ZuritSVP, Business Development · Ordinary SharesSold 11 875 @ $2,04$24K · 2026-03-26

Short positioning

3.0Mshares short+8.2% vs prior

11.17days to cover

69.1%short of daily vol

1.1Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CGEN.NRCanonical

— · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

Net income (YoY) (2025-12-31 vs 2024-12-31): 348.4%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 159.3%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 218.6%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -8.3%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 36.2%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 87.1%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 310.4%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 337.5%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 161.1%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -36.2%Derived (calculated)
Net margin (FY 2025-12-31): 48.6%Derived (calculated)
Gross margin (FY 2025-12-31): 87.3%Derived (calculated)
Return on equity (FY 2025-12-31): 34.4%Derived (calculated)
Return on assets (FY 2025-12-31): 22.6%Derived (calculated)
Current ratio (FY 2025-12-31): 6.56xDerived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 337.5%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 397.0%Derived (calculated)
Operating cash flow (annual): USD 31.63MSEC XBRL filing
Cash & equivalents (annual): USD 90.6MSEC XBRL filing
Shareholders' equity (annual): USD 102.73MSEC XBRL filing
Operating income (annual): USD 31.33MSEC XBRL filing
Revenue (annual): USD 72.76MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-08-03EVENTQ2 2026 earnings (expected) estimated date

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-05-18FILINGZK2635352 →

2026-04-24 00:00 UTCINSIDER33 insider transactions — 2026-04 · $120k gross 12 derivative

2026-04-24INSIDERLevine Zurit transacted 2.0k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-24INSIDERLevine Zurit sold 2.0k sh Ordinary Shares — SVP, Business Development ~$6k

2026-04-24INSIDEROphir Eran transacted 5.0k sh Ordinary Shares — Director, President and CEO ~$4k

2026-04-24INSIDEROphir Eran sold 5.0k sh Ordinary Shares — Director, President and CEO ~$16k

2026-04-24INSIDEROphir Eran disposed of 5.0k sh Share Option (right to buy) — Director, President and CEO

2026-04-24INSIDERLevine Zurit disposed of 2.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-14INSIDEROphir Eran transacted 5.0k sh Ordinary Shares — Director, President and CEO ~$4k

2026-04-14INSIDEROphir Eran sold 5.0k sh Ordinary Shares — Director, President and CEO ~$15k

2026-04-14INSIDERLevine Zurit transacted 2.0k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-14INSIDERLevine Zurit sold 2.0k sh Ordinary Shares — SVP, Business Development ~$6k

2026-04-14INSIDERLevine Zurit disposed of 2.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-14INSIDEROphir Eran disposed of 5.0k sh Share Option (right to buy) — Director, President and CEO

2026-04-10INSIDERLevine Zurit transacted 1.1k sh Ordinary Shares — SVP, Business Development ~$1k

2026-04-10INSIDERLevine Zurit transacted 2.0k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-10INSIDERLevine Zurit sold 3.1k sh Ordinary Shares — SVP, Business Development ~$8k

2026-04-10INSIDERLevine Zurit disposed of 1.1k sh Share Option (right to buy) — SVP, Business Development

2026-04-10INSIDERLevine Zurit disposed of 2.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-08INSIDERLevine Zurit transacted 4.4k sh Ordinary Shares — SVP, Business Development ~$4k

2026-04-08INSIDERLevine Zurit transacted 1.0k sh Ordinary Shares — SVP, Business Development ~$1k

2026-04-08INSIDERLevine Zurit sold 5.4k sh Ordinary Shares — SVP, Business Development ~$13k

2026-04-08INSIDERLevine Zurit disposed of 4.4k sh Share Option (right to buy) — SVP, Business Development

2026-04-08INSIDERLevine Zurit disposed of 1.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-07INSIDERLevine Zurit sold 2.5k sh Ordinary Shares — SVP, Business Development ~$6k

2026-04-07INSIDERLevine Zurit transacted 2.5k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-07INSIDERLevine Zurit disposed of 2.5k sh Share Option (right to buy) — SVP, Business Development

2026-04-01INSIDERLevine Zurit transacted 1.0k sh Ordinary Shares — SVP, Business Development ~$1k

2026-04-01INSIDEROphir Eran transacted 5.6k sh Ordinary Shares — Director, President and CEO ~$5k

2026-04-01INSIDEROphir Eran sold 5.6k sh Ordinary Shares — Director, President and CEO ~$12k

2026-04-01INSIDERLevine Zurit sold 3.5k sh Ordinary Shares — SVP, Business Development ~$8k

2026-04-01INSIDERLevine Zurit transacted 2.5k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-01INSIDERLevine Zurit disposed of 2.5k sh Share Option (right to buy) — SVP, Business Development

2026-04-01INSIDERLevine Zurit disposed of 1.0k sh Share Option (right to buy) — SVP, Business Development

Showing the 40 most recent of 56 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread